|
|
| Line 47: |
Line 47: |
|
| |
|
| ==Medical Therapy== | | ==Medical Therapy== |
| *Pharmacologic medical therapy is recommended among patients with [disease subclass 1], [disease subclass 2], and [disease subclass 3]. | | Treatment goals in systemic lupus erythematosus (SLE) include: |
| *Pharmacologic medical therapies for [disease name] include (either) [therapy 1], [therapy 2], and/or [therapy 3]. | | * Ensure long-term survival |
| *Empiric therapy for [disease name] depends on [disease factor 1] and [disease factor 2]. | | * Achieve the lowest possible disease activity |
| *Patients with [disease subclass 1] are treated with [therapy 1], whereas patients with [disease subclass 2] are treated with [therapy 2]. | | * Prevent organ damage |
| ===Disease Name===
| | * Minimize [[drug toxicity]] |
| | * Improve quality of life |
|
| |
|
| * '''1 Stage 1 - Name of stage'''
| | ===== General treatment ===== |
| ** 1.1 '''Specific Organ system involved 1'''
| | * [[Hydroxychloroquine]]: 200 to 400 mg daily as a single daily dose or in 2 divided doses. |
| *** 1.1.1 '''Adult'''
| | ** Generally, all patients with any type of SLE manifestation should be treated with [[hydroxychloroquine]] regardless of the severity of the disease. |
| **** Preferred regimen (1): [[drug name]] 100 mg PO q12h for 10-21 days '''(Contraindications/specific instructions)''' | | The treatment choice for systemic lupus erythematosus (SLE) is varied based on the severity of the disease and symptoms: |
| **** Preferred regimen (2): [[drug name]] 500 mg PO q8h for 14-21 days
| | * Mild cases are defined as disease pattern with one or two organ involvement. |
| **** Preferred regimen (3): [[drug name]] 500 mg q12h for 14-21 days
| | * Moderate cases are defined as more than 2 organ involvement during disease flares with low grade of involvement and complications or one or two organ involvement with more extensive involvements. |
| **** Alternative regimen (1): [[drug name]] 500 mg PO q6h for 7–10 days
| | * Severe cases are defined as presentation of the disease with life threatening complications and multiple (more than 2) organ involvements. |
| **** Alternative regimen (2): [[drug name]] 500 mg PO q12h for 14–21 days
| |
| **** Alternative regimen (3): [[drug name]] 500 mg PO q6h for 14–21 days
| |
| *** 1.1.2 '''Pediatric'''
| |
| **** 1.1.2.1 (Specific population e.g. '''children < 8 years of age''')
| |
| ***** Preferred regimen (1): [[drug name]] 50 mg/kg PO per day q8h (maximum, 500 mg per dose)
| |
| ***** Preferred regimen (2): [[drug name]] 30 mg/kg PO per day in 2 divided doses (maximum, 500 mg per dose)
| |
| ***** Alternative regimen (1): [[drug name]]10 mg/kg PO q6h (maximum, 500 mg per day)
| |
| ***** Alternative regimen (2): [[drug name]] 7.5 mg/kg PO q12h (maximum, 500 mg per dose)
| |
| ***** Alternative regimen (3): [[drug name]] 12.5 mg/kg PO q6h (maximum, 500 mg per dose) | |
| ****1.1.2.2 (Specific population e.g. ''''''children < 8 years of age'''''')
| |
| ***** Preferred regimen (1): [[drug name]] 4 mg/kg/day PO q12h（maximum, 100 mg per dose）
| |
| ***** Alternative regimen (1): [[drug name]] 10 mg/kg PO q6h (maximum, 500 mg per day)
| |
| ***** Alternative regimen (2): [[drug name]] 7.5 mg/kg PO q12h (maximum, 500 mg per dose)
| |
| ***** Alternative regimen (3): [[drug name]] 12.5 mg/kg PO q6h (maximum, 500 mg per dose)
| |
| ** 1.2 '''Specific Organ system involved 2'''
| |
| *** 1.2.1 '''Adult'''
| |
| **** Preferred regimen (1): [[drug name]] 500 mg PO q8h
| |
| *** 1.2.2 '''Pediatric'''
| |
| **** Preferred regimen (1): [[drug name]] 50 mg/kg/day PO q8h (maximum, 500 mg per dose)
| |
| | |
| * 2 '''Stage 2 - Name of stage'''
| |
| ** 2.1 '''Specific Organ system involved 1 '''
| |
| **: '''Note (1):'''
| |
| **: '''Note (2)''':
| |
| **: '''Note (3):'''
| |
| *** 2.1.1 '''Adult'''
| |
| **** Parenteral regimen
| |
| ***** Preferred regimen (1): [[drug name]] 2 g IV q24h for 14 (14–21) days
| |
| ***** Alternative regimen (1): [[drug name]] 2 g IV q8h for 14 (14–21) days
| |
| ***** Alternative regimen (2): [[drug name]] 18–24 MU/day IV q4h for 14 (14–21) days | |
| **** Oral regimen
| |
| ***** Preferred regimen (1): [[drug name]] 500 mg PO q8h for 14 (14–21) days
| |
| ***** Preferred regimen (2): [[drug name]] 100 mg PO q12h for 14 (14–21) days
| |
| ***** Preferred regimen (3): [[drug name]] 500 mg PO q12h for 14 (14–21) days
| |
| ***** Alternative regimen (1): [[drug name]] 500 mg PO q6h for 7–10 days
| |
| ***** Alternative regimen (2): [[drug name]] 500 mg PO q12h for 14–21 days
| |
| ***** Alternative regimen (3):[[drug name]] 500 mg PO q6h for 14–21 days
| |
| *** 2.1.2 '''Pediatric'''
| |
| **** Parenteral regimen | |
| ***** Preferred regimen (1): [[drug name]] 50–75 mg/kg IV q24h for 14 (14–21) days (maximum, 2 g)
| |
| ***** Alternative regimen (1): [[drug name]] 150–200 mg/kg/day IV q6–8h for 14 (14–21) days (maximum, 6 g per day)
| |
| ***** Alternative regimen (2): [[drug name]] 200,000–400,000 U/kg/day IV q4h for 14 (14–21) days (maximum, 18–24 million U per day) ''''''(Contraindications/specific instructions)''''''
| |
| **** Oral regimen
| |
| ***** Preferred regimen (1): [[drug name]] 50 mg/kg/day PO q8h for 14 (14–21) days (maximum, 500 mg per dose)
| |
| ***** Preferred regimen (2): [[drug name]] '''(for children aged ≥ 8 years)''' 4 mg/kg/day PO q12h for 14 (14–21) days (maximum, 100 mg per dose)
| |
| ***** Preferred regimen (3): [[drug name]] 30 mg/kg/day PO q12h for 14 (14–21) days (maximum, 500 mg per dose)
| |
| ***** Alternative regimen (1): [[drug name]] 10 mg/kg PO q6h 7–10 days (maximum, 500 mg per day)
| |
| ***** Alternative regimen (2): [[drug name]] 7.5 mg/kg PO q12h for 14–21 days (maximum, 500 mg per dose)
| |
| ***** Alternative regimen (3): [[drug name]] 12.5 mg/kg PO q6h for 14–21 days (maximum,500 mg per dose) | |
| ** 2.2 '<nowiki/>'''''Other Organ system involved 2''''''
| |
| **: '''Note (1):'''
| |
| **: '''Note (2)''':
| |
| **: '''Note (3):'''
| |
| *** 2.2.1 '''Adult'''
| |
| **** Parenteral regimen
| |
| ***** Preferred regimen (1): [[drug name]] 2 g IV q24h for 14 (14–21) days
| |
| ***** Alternative regimen (1): [[drug name]] 2 g IV q8h for 14 (14–21) days
| |
| ***** Alternative regimen (2): [[drug name]] 18–24 MU/day IV q4h for 14 (14–21) days
| |
| **** Oral regimen
| |
| ***** Preferred regimen (1): [[drug name]] 500 mg PO q8h for 14 (14–21) days
| |
| ***** Preferred regimen (2): [[drug name]] 100 mg PO q12h for 14 (14–21) days
| |
| ***** Preferred regimen (3): [[drug name]] 500 mg PO q12h for 14 (14–21) days
| |
| ***** Alternative regimen (1): [[drug name]] 500 mg PO q6h for 7–10 days
| |
| ***** Alternative regimen (2): [[drug name]] 500 mg PO q12h for 14–21 days
| |
| ***** Alternative regimen (3):[[drug name]] 500 mg PO q6h for 14–21 days
| |
| *** 2.2.2 '''Pediatric'''
| |
| **** Parenteral regimen
| |
| ***** Preferred regimen (1): [[drug name]] 50–75 mg/kg IV q24h for 14 (14–21) days (maximum, 2 g)
| |
| ***** Alternative regimen (1): [[drug name]] 150–200 mg/kg/day IV q6–8h for 14 (14–21) days (maximum, 6 g per day)
| |
| ***** Alternative regimen (2): [[drug name]] 200,000–400,000 U/kg/day IV q4h for 14 (14–21) days (maximum, 18–24 million U per day)
| |
| **** Oral regimen
| |
| ***** Preferred regimen (1): [[drug name]] 50 mg/kg/day PO q8h for 14 (14–21) days (maximum, 500 mg per dose)
| |
| ***** Preferred regimen (2): [[drug name]] 4 mg/kg/day PO q12h for 14 (14–21) days (maximum, 100 mg per dose)
| |
| ***** Preferred regimen (3): [[drug name]] 30 mg/kg/day PO q12h for 14 (14–21) days (maximum, 500 mg per dose)
| |
| ***** Alternative regimen (1): [[drug name]] 10 mg/kg PO q6h 7–10 days (maximum, 500 mg per day)
| |
| ***** Alternative regimen (2): [[drug name]] 7.5 mg/kg PO q12h for 14–21 days (maximum, 500 mg per dose)
| |
| ***** Alternative regimen (3): [[drug name]] 12.5 mg/kg PO q6h for 14–21 days (maximum,500 mg per dose)
| |
|
| |
|
| ==References== | | ==References== |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:
Overview
There is no treatment for [disease name]; the mainstay of therapy is supportive care.
OR
Supportive therapy for [disease name] includes [therapy 1], [therapy 2], and [therapy 3].
OR
The majority of cases of [disease name] are self-limited and require only supportive care.
OR
[Disease name] is a medical emergency and requires prompt treatment.
OR
The mainstay of treatment for [disease name] is [therapy].
OR
The optimal therapy for [malignancy name] depends on the stage at diagnosis.
OR
[Therapy] is recommended among all patients who develop [disease name].
OR
Pharmacologic medical therapy is recommended among patients with [disease subclass 1], [disease subclass 2], and [disease subclass 3].
OR
Pharmacologic medical therapies for [disease name] include (either) [therapy 1], [therapy 2], and/or [therapy 3].
OR
Empiric therapy for [disease name] depends on [disease factor 1] and [disease factor 2].
OR
Patients with [disease subclass 1] are treated with [therapy 1], whereas patients with [disease subclass 2] are treated with [therapy 2].
Medical Therapy
Treatment goals in systemic lupus erythematosus (SLE) include:
- Ensure long-term survival
- Achieve the lowest possible disease activity
- Prevent organ damage
- Minimize drug toxicity
- Improve quality of life
General treatment
- Hydroxychloroquine: 200 to 400 mg daily as a single daily dose or in 2 divided doses.
- Generally, all patients with any type of SLE manifestation should be treated with hydroxychloroquine regardless of the severity of the disease.
The treatment choice for systemic lupus erythematosus (SLE) is varied based on the severity of the disease and symptoms:
- Mild cases are defined as disease pattern with one or two organ involvement.
- Moderate cases are defined as more than 2 organ involvement during disease flares with low grade of involvement and complications or one or two organ involvement with more extensive involvements.
- Severe cases are defined as presentation of the disease with life threatening complications and multiple (more than 2) organ involvements.
References
Template:WH
Template:WS